LimFlow System
LimFlow, Inc. · Decision date Jan 7, 2026
What did the FDA decide?
FDA records P220025/S008 as a supplement to PMA P220025, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 7, 2026.
FDA approval order statement
a manufacturing process change for the soft tip bond
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Jan 7, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P220025/S008
- Regulatory pathway
- PMA supplement
- Applicant
- LimFlow, Inc.
- Product code
- QWN
- Decision code
- OK30
- Decision date
- Jan 7, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent graft, infrapopliteal, venous arterialization.
- Applicant
- LimFlow, Inc.
- Product code
- QWN
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P220025/S007 · Related supplement
LimFlow System
P220025/S008 received
Application receipt date recorded by FDA.
P220025/S008 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P220025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LimFlow SystemP220025/S007 | LimFlow, Inc. | PMA supplement | Oct 22, 2025 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
LimFlow, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3031 Tisch Way - 110 Plz. W., San Jose, CA, 95128
Sources and methodology
- Original FDA record: P220025/S008
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records